Neoadjuvant chemo well-tolerated in poor-risk rectal cancer
5 February 2010
| by Nicola Garrett
Neoadjuvant chemotherapy with capecitabine and oxaliplatin in potentially operable patients with poor-risk rectal cancer was well-tolerated and showed ‘promising’ anti-tumour activity, results of a phase II study shows....
Want to read complete article? Please Sign in or Register.